Toggle Main Menu Toggle Search

Open Access padlockePrints

The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells

Lookup NU author(s): Dr Elizabeth Veal

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Differentiation of the human embryonal carcinoma cell line NTERA-2 is characterized by changes in morphology, altered patterns of gene expression, reduced proliferative potential, and a loss of tumorigenicity. The cellular repressor of E1A-stimulated genes, CREG, was previously shown to antagonize transcriptional activation and cellular transformation by the Adenovirus E1A oncoprotein. These properties suggested that CREG may function to inhibit cell growth and/or promote differentiation. Here we show that CREG is a secreted glycoprotein which enhances differentiation of NTERA-2 cells. Northern blot analysis reveals that, although CREG mRNA is widely expressed in adult tissues, CREG mRNA is not significantly expressed in pluripotent mouse embryonic stem cells or NTERA-2 embryonal carcinoma cells. CREG mRNA is rapidly induced upon in vitro differentiation of both mouse embryonic stem cells and human NTERA-2 cells. We show that constitutive expression of CREG in NTERA-2 cells enhances neuronal differentiation upon treatment with retinoic acid. Media enriched in CREG was also found to promote NTERA-2 differentiation in the absence of an inducer such as retinoic acid. These studies suggest that secreted CREG protein participates in a signaling cascade important for differentiation of pluripotent stem cells such as those found in teratocarcinomas.


Publication metadata

Author(s): Veal E, Groisman R, Eisenstein M, Gill G

Publication type: Article

Publication status: Published

Journal: Oncogene

Year: 2000

Volume: 19

Issue: 17

Pages: 2120-2128

ISSN (print): 0950-9232

ISSN (electronic): 1476-5594

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1038/sj.onc.1203529

DOI: 10.1038/sj.onc.1203529

PubMed id: 10815803


Altmetrics

Altmetrics provided by Altmetric


Share